IF a sequential, lineage-gated combinatorial regimen — consisting of: (i) tamoxifen-induced Aldh1l1-CreER^T2 astrocyte pre-labeling (75 mg/kg i.p., 5 days, 2 weeks pre-surgery) to permanently mark SNpc astrocytes with a Rosa26-tdTomato reporter; followed by (ii) bilateral stereotactic co-injection into the substantia nigra pars compacta (SNpc) of aged (20–22 month) male C57BL/6J mice with established bilateral 6-OHDA lesions of: (a) Cre-dependent AAV9-DIO-NeuroD1-P2A-Nurr1 (EF1α promoter; 2×10^12 vg/mL, 1 µL/hemisphere) and (b) GDNF-functionalized 12 nm gold nanoparticles (AuNP-GDNF; ~85–170 GDNF peptide conjugates/particle, 5 µg GDNF equivalent/hemisphere) —

is administered to aged 6-OHDA-lesioned C57BL/6J mice bearing established (~60%) bilateral SNpc TH+ neuron loss,

THEN ≥50% restoration of TH+ neuron counts (relative to pre-lesion stereological baseline), confirmed exclusively in tdTomato+ lineage-traced cells by dual TH/tdTomato/DAT immunohistochemistry, will be observed at 12 weeks post-injection, exceeding NeuroD1 monotherapy restoration (predicted ≤25%) by ≥25 percentage points, with concurrent ≥40% improvement in rotarod latency-to-fall and striatal dopamine release ≥3-fold above vehicle controls by in vivo microdialysis,

BECAUSE the following causal chain operates:

1. Aldh1l1-CreER^T2 + tamoxifen permanently recombines Rosa26-tdTomato in SNpc astrocytes before any viral exposure, creating an unambiguous lineage stamp that cannot be contaminated by post-injection AAV leakage into endogenous neurons — directly solving the promoter-leakage artifact that caused false-positive conversions when GFAP-AAV reporters were used without prior genetic fate mapping (NeuroD1 lineage tracing controversy described in the evidence set, Wang et al. 2021, PMID: 34559323; also Hoang et al. Cell 2022 critiques cited in the evidence synthesis).

2. Cre-dependent AAV9-DIO-NeuroD1-P2A-Nurr1 is expressed only in Cre-recombined (tdTomato+) astrocytes, ensuring that any TH+ neuron carrying the tdTomato label is a bona fide astrocyte-derived converted cell — not an endogenous neuron erroneously transduced by a leaky promoter (NeuroD1 AAV midbrain conversion literature, Wu et al. 2020, PMID: 32353338, as discussed in the evidence synthesis).

3. The bicistronic NeuroD1-P2A-Nurr1 cassette supplies two orthogonal dopaminergic determinants simultaneously: NeuroD1 drives generic neuronal identity conversion (action potential competence, synaptic protein expression) (NeuroD1 AAV induces astrocyte-to-neuron conversion in adult mouse cortex with converted neurons showing action potentials and synaptic responses)[https://pmc.ncbi.nlm.nih.gov/articles/PMC6952185/], while Nurr1 (NR4A2) is the master transcription factor for midbrain dopaminergic identity, activating TH, DAT, AADC, and VMAT2 — genes NeuroD1 alone cannot reliably induce in the SNpc [SPECULATIVE: the Nurr1 addition to NeuroD1 specifically in SNpc astrocyte reprogramming is untested but is mechanisticall...

SENS category: RepleniSENS

Key references: • PMID: 34559323 • PMID: 32353338